Phanes is a biotech company focused on discovery and development of innovative biologic drugs in oncology and eye diseases.
Phanes Therapeutics' mission is to become a major source of innovation in the biopharma industry.
Phanes Therapeutics was founded in 2016 by Ming Wang. The company is headquartered in San Diego, California and Shanghai, China.
Phanes’ bispecific antibody technology platform is PACbody™, a proprietary approach for constructing bispecific antibodies that have native IgG-like structures with superb CMC characteristics. PACbodies can be designed to be fit for platform in the conventional manufacturing process for monoclonal antibodies.
Phanes is also developing ATACCbody™, which allows for construction of conjugated IgG-like bispecific antibodies (ATACCbodies) whose activities are modulated by the environment they are in.
Phanes has completed a $40M Series B financing on May 07, 2021. The round was led by Sequoia Capital China, with participation from Dyee Capital, Volcanics Venture, and Delos Capital.